- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02291913
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Myers, Florida, United States, 33916
- Florida Cancer Specialists-South
-
Hollywood, Florida, United States, 33021
- Memorial Cancer Center
-
Pensacola, Florida, United States, 32503
- Woodlands Medical Specialists
-
West Palm Beach, Florida, United States, 33401
- Florida Cancer Specialists-East
-
-
Indiana
-
Terre Haute, Indiana, United States, 47802
- Hope Cancer Center
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Tennessee Oncology
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology PLLC
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Center for Cancer and Blood Disorders
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologic diagnosis of unresectable, locally recurrent or MBC.
- ER and/or PR-positive tumors with staining by immunohistochemistry (IHC) based on the most recent biopsy.
- Only 1 previous chemotherapy regimen for MBC. Patients progressing while receiving adjuvant endocrine therapy or progressing <12 months from completion of adjuvant endocrine therapy are eligible.
Progressed on anti-estrogen therapy (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy) defined as:
- Recurrence while on, or within 12 months of end of anti-estrogen therapy for early stage breast cancer, or
- Progression while on, or within one month of anti-estrogen therapy for locally advanced or metastatic breast cancer.
Note: No washout for anti-estrogen therapy required. Anti-estrogen therapy does not have to be the last treatment prior to study entry.
- Post-menopausal or pre/peri-menopausal women on tamoxifen. LHRH agonists may be used to render ovarian suppression with postmenopausal ranges of estradiol or FSH per institutional guidelines.
HER2-negative breast cancer, defined as follows:
- Fluorescent In Situ Hybridization (FISH)-negative (FISH ratio <2.0), or
- IHC 0-1+, or
- IHC 2-3+ AND FISH-negative (FISH ratio <2.0).
- Measureable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable bone lesions, lytic or mixed, in absence of measureable disease by RECIST criteria.
- Adequate hematologic, hepatic and renal function.
- International normalized ratio (INR) ≤1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy).
- Age ≥ 18 years.
- ECOG Performance Status score of 0-2.
- Life expectancy of ≥ 12 weeks.
Exclusion Criteria:
- Previous therapy or known intolerance/hypersensitivity with any approved or investigational mTOR inhibitor (e.g., temsirolimus, everolimus, sirolimus).
- Patients who are ≤21 days after their most recent chemotherapy and have not recovered from side effects.
- Use of an investigational drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of everolimus. For investigational drugs for which 5 half-lives is ≤21 days, a minimum of 10 days between termination of the investigational drug and administration of everolimus is required.
- Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days for metastatic disease prior to first dose of everolimus or has not recovered from side effects of such therapy.
- Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if there is no evidence of central nervous system (CNS) disease progression, and at least 2 weeks have elapsed since treatment. Patients are not permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs) during the study and should not be receiving chronic corticosteroid therapy for CNS metastases.
- Patients with known active hepatitis B (HBV) or hepatitis C (HCV) infection. Patients with risk factors for hepatitis must have HBV DNA and HCV RNA testing by PCR, and are ineligible if these tests are positive.
- Patients receiving immunization with attenuated live vaccines within 1 week of study entry or during study period.
NOTE: There are additional inclusion/exclusion criteria. The study center will determine patient eligibility and respond to any questions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: everolimus
Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy).
Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
|
Other Names:
Anti-estrogen therapy
Anti-estrogen therapy
Anti-estrogen therapy
Anti-estrogen therapy
Anti-estrogen therapy
Anti-estrogen therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression Free Survival (PFS)
Time Frame: up to 3 years
|
PFS is defined as the time from Day 1 of study drug administration to disease progression as defined by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria, or death on study.
Participants who are alive and free from disease progression will be censored at the date of last radiologic tumor assessment.
Participants who receive non-protocol therapy (subsequent therapy) prior to incurring an event will be censored at the date of last tumor assessment prior to the start of subsequent therapy.
Participants who do not have a post-baseline tumor assessment will be censored at the date of first treatment (Day 1).
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Adverse Events (AEs) as a Measure of Safety and Tolerability
Time Frame: Up to 20 months
|
Assessments were made through analysis of the reported incidence of treatment-emergent AEs.
All participants who received at least one dose of protocol treatment were followed for safety.
Adverse events were collected from day of first dose to 30 days after last protocol treatment and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
|
Up to 20 months
|
Number of Patients With an Objective Response (CR or PR) Also Called the Overall Response Rate (ORR).
Time Frame: every 8 weeks until discontinuation, up to 20 months
|
Defined as the number of patients with objective evidence of complete or partial response (CR or PR) using RECIST version 1.1.
A CR is the complete disappearance of all target lesions.
A PR is a decrease of 30% or more of the diameter(s) of all target lesions from the baseline sum of diameters.
|
every 8 weeks until discontinuation, up to 20 months
|
Number of Participants With CR, PR, or 6 Months of SD Also Called Clinical Benefit Rate (CBR)
Time Frame: Up to 20 months
|
The proportion of patients with Complete Response (CR) or Partial Response (PR) or 6 months or more of Stable Disease (SD).
A CR is the complete disappearance of all target lesions.
A PR is a decrease of 30% or more of the diameter(s) of all target lesions from the baseline sum of diameters.
SD is not meeting the criteria for PR or a 20% increase in target lesions called Progressive Disease (PD).
|
Up to 20 months
|
Median Time From First Occurrence of CR or PR to Disease Progression or Death Also Called Duration of Response (DOR)
Time Frame: every 8 weeks until discontinuation, up to 20 months
|
Only those patients who achieved Complete Response or Partial Response will be included in the summaries of DOR.
DOR is defined as time from first date of response of CR or PR to disease progression or death as defined by RECIST v1.1 criteria.
Participants who are alive and free from disease progression will be censored at the date of last tumor assessment.
Patients who receive non-protocol therapy (subsequent therapy) prior to incurring an event will be censored at the date of last tumor assessment prior to the start of subsequent therapy.
A CR is the complete disappearance of all target lesions.
A PR is a decrease of 30% or more of the diameter(s) of all target lesions from the baseline sum of diameters.
|
every 8 weeks until discontinuation, up to 20 months
|
Median Overall Survival (OS)
Time Frame: up to 3 years from first treatment
|
Defined as the time from date of first study treatment to date of death due to any cause.
Patients who are alive will be censored at the date of last known date alive.
|
up to 3 years from first treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Denise A. Yardley, MD, SCRI Development Innovations, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Letrozole
- Fulvestrant
- Tamoxifen
- Everolimus
- Anastrozole
- Exemestane
Other Study ID Numbers
- SCRI BRE 212
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Everolimus
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
The Netherlands Cancer InstituteActive, not recruitingNeuroendocrine CarcinomasNetherlands
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
University of LuebeckTerminatedCoronary Artery DiseaseGermany
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of
-
Centre Leon BerardSuspended
-
Leiden University Medical CenterUnknownHead and Neck CancerNetherlands